SARS-CoV-2 IgG Test (EUA)

Simoa® Semi-Quantitative SARS-CoV-2 IgG Antibody Test

Immunoassay for the qualitative and semi-quantitative determination of antibodies to the SARS-CoV-2 spike protein. For use under the Emergency Use Authorization (EUA) only.

The Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test is an automated paramagnetic microbead-based immunoassay intended for qualitative and semi-quantitative detection of IgG antibodies to SARS-CoV-2 in human serum and dipotassium EDTA plasma using the Quanterix HD-X immunoassay system. The Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARSCoV-2, indicating recent or prior infection.